Work

109P Zongertinib for previously treated HER2-mutant advanced non-small cell lung cancer: A single center experience

Year: 2026

Type: article

Abstract: HER2 mutations are present in 2-4% of advanced non-small cell lung cancer (NSCLC) cases. The HER2 YVMA (i.e. A775_G776YVMA/Y772_A775dup) mutation is the most common mutation found in HER2-mutant NSCLC and is estimated to occur in approximately 40-60% of cases. Zongertinib is a HER2-selective tyrosine kinase inhibitor which recently received accelerated approval by the U.S. Federal Drug Administration for the treatment of previously treated HER2-mutant NSCLC. We describe our experience treating patients with zongertinib at an academic center in a diverse, urban U.S.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.106251

Authors: J.F. Kong, R. Ni, J. Sabari

Institutions: New York University, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910